Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,462.40
(
0.44%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
99.07
(
0.30%
)
Bitcoin
70,501.45
(
-1.13%
)
News Focus
News Focus
Post# of 257288
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: BTH post# 132692

Monday, 12/12/2011 7:10:29 PM

Monday, December 12, 2011 7:10:29 PM

Post# of 257288
Navidea (NEOP) licenses Alzheimer’s imaging agent from AZN:

http://finance.yahoo.com/news/Neoprobe-Licenses-AstraZeneca-bw-929146885.html?x=0

Financial terms of the in-licensing agreement include an upfront payment of $5 million to AstraZeneca and a series of contingent milestone payments including up to $6.5 million in potential payments based on the achievement of clinical development and regulatory filing milestones and up to additional $11 million due following the receipt of regulatory approvals and the initiation of commercial sales.

LOL—this product is not going to be a blockbuster, evidently.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today